EoE in Pediatric Patients: Managing Adverse Events and Treatment Choices

EP: 1.Understanding EoE Pathophysiology: Age-Dependent Challenges

EP: 2.EoE Management: Timely Diagnosis and Multifaceted Treatment Goals

EP: 3.Optimizing EoE Care in Pediatric Patients: Treatments and Shared Decision-Making

Now Viewing

EP: 4.EoE in Pediatric Patients: Managing Adverse Events and Treatment Choices

EP: 5.Overcoming Treatment Challenges in EoE

EP: 6.Future EoE Treatments and Practices

This is a video synopsis/summary of an Insights involving Mirna Chehade, MD, MPH.

Chehade discusses the impact of adverse events on treatment decisions for pediatric eosinophilic esophagitis (EoE), considering the severity and manageability of side effects. Biologics are envisioned for refractory cases or those with adherence challenges, particularly for patients aged 12 and older, with dupilumab being FDA-approved. Route of administration considerations between oral and injection therapies depend on patient preferences.

The use of specialty pharmacies is acknowledged positively for delivery convenience, but potential paperwork challenges in obtaining insurance approval for biologics are recognized. The summary highlights the careful evaluation required in balancing treatment efficacy, patient preferences, and practical considerations in pediatric EoE management.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.